Macrophages offer a paradigm switch for CNS delivery of therapeutic proteins

Nanomedicine

Volumn 9, Issue 9, 2014, Pages 1403-1422

  Klyachko, Natalia L ^a,b   Haney, Matthew J ^b   Zhao, Yuling ^b   Manickam, Devika S ^b   Mahajan, Vivek ^b,c   Suresh, Poornima ^b,c   Hingtgen, Shawn D ^d   Mosley, R Lee ^b   Gendelman, Howard E ^b   Kabanov, Alexander V ^a,b   Batrakova, Elena V ^b,d  

^a MOSCOW STATE UNIVERSITY   (Russian Federation)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

blood brain barrier; catalase; cell mediated drug delivery; neuroinflammation

Indexed keywords

CATALASE; DRUG CARRIER; GAMMA INTERFERON; HYDROGEN PEROXIDE; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; MACROGOL; MANNOSE RECEPTOR; POLYELECTROLYTE; PRONASE; PYROXYLIN; TRYPSIN; CROSS LINKING REAGENT; NANOCAPSULE;

ACIDIFICATION; ACTIVE TRANSPORT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BONE MARROW DERIVED MACROPHAGE; BRAIN; CELL FREE SYSTEM; CELL MEMBRANE; CELL PROTECTION; CENTRAL NERVOUS SYSTEM; COMPLEX FORMATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DEGRADATION; DOPAMINERGIC NERVE CELL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PACKAGING; DRUG RELEASE; DRUG STABILITY; DRUG TRANSPORT; ELECTROPHORESIS; ENCEPHALITIS; ENDOPLASMIC RETICULUM; ENDOSOME; ENZYME ACTIVITY; HYDRODYNAMICS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SPACE; LIGHT SCATTERING; LYSOSOME; MALE; MEMBRANE POTENTIAL; MESENCEPHALON; MICELLE; MITOCHONDRION; MOLECULAR WEIGHT; MONOCYTE; MOUSE; NERVE REGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARTICLE SIZE; PH; PHENOTYPE; PROTEIN DENATURATION; PROTEIN SECRETION; SPECTROPHOTOMETRY; SUBSTANTIA NIGRA PARS COMPACTA; SUSTAINED DRUG RELEASE; THERAPY EFFECT; WESTERN BLOTTING; ZETA POTENTIAL; ANIMAL; BOVINE; C57BL MOUSE; CELL LINE; CHEMISTRY; CYTOLOGY; ENZYME STABILITY; ENZYMOLOGY; MACROPHAGE; MACROPHAGE ACTIVATION; MEDICINAL CHEMISTRY; METABOLISM; NANOMEDICINE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; ULTRASTRUCTURE;

ANIMALS; BLOOD-BRAIN BARRIER; CATALASE; CATTLE; CELL LINE; CHEMISTRY, PHARMACEUTICAL; CROSS-LINKING REAGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ENCEPHALITIS; ENZYME STABILITY; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; NANOCAPSULES; NANOMEDICINE; PARTICLE SIZE;

EID: 84896739983     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.115     Document Type: Article

References (52)

1. Bachis A, Mocchetti I. Brain-derived neurotrophic factor is neuroprotective against human immunodeficiency virus-1 envelope proteins. Ann. NY Acad. Sci. 1053, 247-257 (2005
2. Ying Wang J, Peruzzi F, Lassak A et al. Neuroprotective effects of IGF-I against TNFalpha-induced neuronal damage in HIV-associated dementia. Virology 305(1), 66-76 (2003
3. Koliatsos VE, Clatterbuck RE, Nauta HJ et al. Human nerve growth factor prevents degeneration of basal forebrain cholinergic neurons in primates. Ann. Neurol. 30(6), 831-840 (1991
4. Dogrukol-Ak D, Banks WA, Tuncel N, Tuncel M. Passage of vasoactive intestinal peptide across the blood-brain barrier. Peptides 24(3), 437-444 (2003
5. Perry VH, Bell MD, Brown HC, Matyszak MK. Inflammation in the nervous system. Curr. Opin. Neurobiol. 5(5), 636-641 (1995
6. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38(8), 1285-1291 (1988
7. Busciglio J, Yankner BA. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 378(6559), 776-779 (1995
8. Ebadi M, Srinivasan SK, Baxi MD. Oxidative stress and antioxidant therapy in Parkinson's disease. Prog. Neurobiol. 48(1), 1-19 (1996
9. Wu DC, Teismann P, Tieu K et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine model of Parkinson's disease. Proc. Natl Acad. Sci. USA 100(10), 6145-6150 (2003
10. Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB, Naoi M. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol. Teratol. 24(5), 675-682 (2002
11. Batrakova EV, Li S, Reynolds AD et al. A macrophage- nanozyme delivery system for Parkinson's disease. Bioconjug. Chem. 18(5), 1498-1506 (2007
12. Brynskikh AM, Zhao Y, Mosley RL et al. Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. Nanomedicine (Lond.) 5(3), 379-396 (2010
13. Zhao Y, Haney MJ, Klyachko NL et al. Polyelectrolyte complex optimization for macrophage delivery of redox enzyme nanoparticles. Nanomedicine (Lond.) 6(1), 25-42 (2011
14. Zhao Y, Haney MJ, Mahajan V et al. Active targeted macrophage-mediated delivery of catalase to affected brain regions in models of Parkinson's disease. J. Nanomed. Nanotechnol. S4, pii:003 (2011
15. Batrakova EV, Gendelman HE, Kabanov AV. Cell-mediated drug delivery. Expert Opin. Drug Deliv. 8(4), 415-433 (2011
16. Thomas SR, Witting PK, Drummond GR. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid. Redox Signal. 10(10), 1713-1765 (2008
17. Muzykantov VR. Targeting of superoxide dismutase and catalase to vascular endothelium. J. Control. Release 71(1), 1-21 (2001
18. Supinski GS, Callahan LA. Polyethylene glycol-superoxide dismutase prevents endotoxin-induced cardiac dysfunction. Am. J. Respir. Crit. Care Med. 173(11), 1240-1247 (2006
19. Hood E, Simone E, Wattamwar P, Dziubla T, Muzykantov V. Nanocarriers for vascular delivery of antioxidants. Nanomedicine (Lond.) 6(7), 1257-1272 (2011
20. Thiele L, Merkle HP, Walter E. Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages. Pharm. Res. 20(2), 221-228 (2003
21. Klyachko NL, Manickam DS, Brynskikh AM et al. Cross-linked antioxidant nanozymes for improved delivery to CNS. Nanomedicine 8(1), 119-129 (2012
22. Vinogradov S, Bronich T, Kabanov A. Self-assembly of polyamine-poly(ethylene glycol) copolymers with phosphorothioate oligonucleotides. Bioconjug. Chem. 9(6), 805-812 (1998
23. Dou H, Destache CJ, Morehead JR et al. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 108(8), 2827-2835 (2006
24. Stevenson HC, Katz P, Fauci AS. Purification of human monocytes by counter-current centrifugation elutriation. Cell Immunol. 53(1), 94-103 (1980
25. Ferrari M, Fornasiero M, Isetta A. MTT colorimetric assay for testing macrophage cytotoxic activity in vitro. J. Immunol. Methods 131(2), 165-172 (1990
26. Batrakova E, Han H, Miller D, Kabanov A. Effects of pluronic p85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells. Pharm. Res. 15(10), 1525-1532 (1998
27. Batrakova EV, Vinogradov SV, Robinson SM, Niehoff ML, Banks WA, Kabanov AV. Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery. Bioconjug. Chem. 16(4), 793-802 (2005
28. Haney MJ, Zhao Y, Li S et al. Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells. Nanomedicine (Lond.) 6(7), 1215-1230 (2011
29. Haney MJ, Zhao Y, Harrison EB et al. Specific transfection of inflamed brain by macrophages: a new therapeutic strategy for neurodegenerative diseases. PLoS ONE 8(4), e61852 (2013
30. Papadopoulos S, Jurgens KD, Gros G. Protein diffusion in living skeletal muscle fibers: dependence on protein size, fiber type, and contraction. Biophys. J. 79(4), 2084-2094 (2000
31. Solomatin SV, Bronich TK, Eisenberg A, Kabanov VA, Kabanov AV. Nanomaterials from ionic block copolymers and single-, double-, and triple-tail surfactants. Langmuir 23(5), 2838-2842 (2007
32. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J. Neurosci. 29(43), 13435-13444 (2009
33. Freundt EC, Czapiga M, Lenardo MJ. Photoconversion of LysoTracker Red to a green fluorescent molecule. Cell Res. 17(11), 956-958 (2007
34. Haney MJ, Suresh P, Zhao Y et al. Blood-borne macrophage- neural cell interactions hitchhike endosome networks for cell-based nanozyme brain delivery. Nanomedicine (Lond.) 7(6), 815-833 (2012
35. Stone DK, Reynolds AD, Mosley RL, Gendelman HE. Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid. Redox Signal. 11(9), 2151-2166 (2009
36. Nowacek AS, Miller RL, Mcmillan J et al. NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond.) 4(8), 903-917 (2009
37. Gbadamosi JK, Hunter AC, Moghimi SM. PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. FEBS Lett. 532(3), 338-344 (2002
38. Mizushima Y, Hamano T, Yokoyama K. Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion. Ann. Rheum. Dis. 41(3), 263-267 (1982
39. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci. 66(17), 2873-2896 (2009
40. Hendriks JJ, Teunissen CE, De Vries HE, Dijkstra CD. Macrophages and neurodegeneration. Brain Res. Rev. 48(2), 185-195 (2005
41. Shechter R, Schwartz M. Harnessing monocyte-derived macrophages to control central nervous system pathologies: no longer 'if ' but 'how'. J. Pathol. 229(2), 332-346 (2013
42. Lassmann H, Schmied M, Vass K, Hickey WF. Bone marrow derived elements and resident microglia in brain inflammation. Glia 7(1), 19-24 (1993
43. Vass K, Hickey WF, Schmidt RE, Lassmann H. Bone marrow-derived elements in the peripheral nervous system. An immunohistochemical and ultrastructural investigation in chimeric rats. Lab. Invest. 69(3), 275-282 (1993
44. Pawlowski NA, Kaplan G, Abraham E, Cohn ZA. The selective binding and transmigration of monocytes through the junctional complexes of human endothelium. J. Exp. Med. 168(5), 1865-1882 (1988
45. Lossinsky AS, Shivers RR. Structural pathways for macromolecular and cellular transport across the blood- brain barrier during inflammatory conditions. Review. Histol. Histopathol. 19(2), 535-564 (2004
46. Muller WA. Getting leukocytes to the site of inflammation. Vet. Pathol. 50(1), 7-22 (2013
47. Persidsky Y, Ghorpade A, Rasmussen J et al. Microglial and astrocyte chemokines regulate monocyte migration through the blood-brain barrier in human immunodeficiency virus-1 encephalitis. Am. J. Pathol. 155(5), 1599-1611 (1999
48. Blamire AM, Anthony DC, Rajagopalan B, Sibson NR, Perry VH, Styles P. Interleukin-1beta -induced changes in blood-brain barrier permeability, apparent diffusion coefficient, and cerebral blood volume in the rat brain: a magnetic resonance study. J. Neurosci. 20(21), 8153-8159 (2000
49. Anthony DC, Blond D, Dempster R, Perry VH. Chemokine targets in acute brain injury and disease. Prog. Brain Res. 132, 507-524 (2001
50. Mahmood A, Lu D, Lu M, Chopp M. Treatment of traumatic brain injury in adult rats with intravenous administration of human bone marrow stromal cells. Neurosurgery 53(3), 697-702 (2003
51. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57(2), 178-201 (2008
52. Alvarez JI, Cayrol R, Prat A. Disruption of central nervous system barriers in multiple sclerosis. Biochim. Biophys. Acta 1812(2), 252-264 (2011